Online inquiry

IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7925MR)

This product GTTS-WQ7925MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CSF2 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000758.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1437
UniProt ID P04141
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7925MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5296MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ4572MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ135MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ2035MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ10653MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ406MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ2515MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ9719MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW